The first quarter of 2026 has marked a strong beginning for pharmaceutical innovation. The U.S. FDA approved several novel therapies spanning oncology, rare genetic disorders, dermatology, and metabolic diseases. These approvals highlight ongoing advancements in targeted treatments, biologics, and therapies designed to address unmet medical needs.
Below is a detailed overview of novel drug therapy approvals from January to March 2026, including drug names, active ingredients, approval dates, and their approved indications.
FDA Novel Drug Approvals (January–March 2026)
- Lifyorli (relacorilant)
Approved on March 25, 2026, for the treatment of platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer in patients who have received one to three prior systemic treatment regimens, including at least one containing bevacizumab. - Avlayah (tividenofusp alfa-eknm)
Approved on March 24, 2026, for the treatment of certain patients with Hunter syndrome (Mucopolysaccharidosis type II, MPS II). - Icotyde (icotrokinra)
Approved on March 17, 2026, for moderate-to-severe plaque psoriasis in patients aged 12 years and older, weighing at least 40 kg, who are eligible for systemic therapy or phototherapy. - Lynavoy (linerixibat)
Approved on March 17, 2026, to treat cholestatic pruritus associated with primary biliary cholangitis. - Yuviwel (navepegritide)
Approved on February 27, 2026, to promote linear growth in pediatric patients (aged 2 years and above) with achondroplasia and open epiphyses. - Loargys (pegzilarginase-nbln)
Approved on February 23, 2026, for the treatment of hyperarginemia in both adult and pediatric patients (2 years and older) with Arginase 1 Deficiency, alongside dietary protein restriction. - Bysanti (milsaperidone)
Approved on February 20, 2026, for the treatment of schizophrenia and manic or mixed episodes associated with bipolar I disorder. - Adquey (difamilast)
Approved on February 12, 2026, for the treatment of mild to moderate atopic dermatitis. - Zycubo (copper histidinate)
Approved on January 12, 2026, for the treatment of Menkes disease.
Key Insights
The FDA approvals in Q1 2026 reflect a clear focus on rare diseases, dermatological conditions, and oncology. A significant number of therapies target genetic and metabolic disorders, underscoring the expanding role of precision medicine and biologics in modern healthcare.
Source: FDA Novel Drug Approvals 2026